Research
Research groups
Research grants
PRIMROSE CSF study - A prospective study of the genomic landscape of brain metastasis secondary to breast cancer utilising cell free DNA derived from cerebral spinal fluid.
MAKE 2NDS COUNT (UK)
July 2020 - December 2026
CCP–CANCER UK: Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK) – a prospective companion study for patients with Cancer and COVID-19.
MEDICAL RESEARCH COUNCIL, THE CLATTERBRIDGE CANCER CHARITY (UK)
June 2020 - April 2024
Bench Fees for Atenea Uribe Ojeda (201519967)
AGENCIA NACIONAL DE INVESTIGACIÓN Y DESARROLLO (CHILE)
February 2021 - January 2025
A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadjuvant therapy in ER-positive intermediate recurrence score primary breast cancer (NEO21-RS)
PFIZER LTD (UK)
July 2018 - June 2022
BELLE-CNS: A proof of concept study of BKM120 in HER2 positive breast cancer with brain metastasis following HER2 directed monoclonal antibody therapy
NOVARTIS PHARMACEUTICALS UK LTD (UK), THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST (UK)
October 2015 - September 2017
Stretching the supply routes: ErbB2 gene amplification and endocytic recycling in metastatic breast cancer
BREAST CANCER NOW (UK)
January 2015 - January 2019
Liverpool ECMC (LECMC)
CANCER RESEARCH UK (UK), DEPARTMENT OF HEALTH & SOCIAL CARE (UK)
April 2023 - March 2028
Provision of a MassArray Mass-spectrometry based multiplex genotyping platform (Agena Biosciences).
MEDICAL RESEARCH COUNCIL
July 2023 - June 2025
Pan-Tumour Trial of Cox-Inhibitor and Immune Checkpoint Blockade (LION)
THE CHRISTIE NHS FOUNDATION TRUST (UK)
September 2021 - August 2028
Three Pillars Study: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole, trastuzumab plus tucatinib as neoadjvuant treatment for ER-positive, HER2-positive early breast cancer
SEAGEN INC (USA)
August 2022 - August 2027
PROgesterone as a Steroid SParing agent against oEdema occurring with bRain cancers
DEPARTMENT OF HEALTH & SOCIAL CARE (UK)
August 2021 - August 2024